Literature DB >> 7909711

Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia.

S M Halstead1, T R Barnes, J C Speller.   

Abstract

In a sample of 120 long-stay in-patients who fulfilled DSM-III-R criteria for schizophrenia, chronic akathisia and pseudoakathisia were relatively common, with prevalence figures of 24% and 18%, respectively. Compared with patients without evidence of chronic akathisia, those patients with the condition were significantly younger, were receiving significantly higher doses of antipsychotic medication, and were more likely to be receiving a depot antipsychotic. Patients who experienced the characteristic inner restlessness and compulsion to move of akathisia also reported marked symptoms of dysphoria, namely tension, panic, irritability and impatience. The findings support the suggestion that dysphoric mood is an important feature of akathisia. Male patients appeared to be at an increased risk of pseudoakathisia. No significant relation was found between chronic akathisia and tardive dyskinesia, although there was a trend for trunk and limb dyskinesia to be commonest in patients with chronic akathisia while orofacial dyskinesia was most frequently observed in those with pseudoakathisia. Akathisia may mask the movements of tardive dyskinesia in the lower limb. There was no evidence that akathisia was associated with positive or negative symptoms of schizophrenia nor with depression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909711     DOI: 10.1192/bjp.164.2.177

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  17 in total

1.  Mind and movement: the neuropsychiatry of movement disorders.

Authors:  Belinda R Lennox; Graham G Lennox
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

2.  Antipsychotic-induced movement disorders: evaluation and treatment.

Authors:  Maju Mathews; Sylvia Gratz; Babatunde Adetunji; Vinu George; Manu Mathews; Biju Basil
Journal:  Psychiatry (Edgmont)       Date:  2005-03

Review 3.  The primary care of patients with schizophrenia: a search for good practice.

Authors:  T Burns; T Kendrick
Journal:  Br J Gen Pract       Date:  1997-08       Impact factor: 5.386

Review 4.  Anticholinergics for neuroleptic-induced acute akathisia.

Authors:  J Rathbone; K Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

5.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

Review 6.  Benzodiazepines for neuroleptic-induced acute akathisia.

Authors:  A R Lima; K Soares-Weiser; J Bacaltchuk; T R Barnes
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia.

Authors:  A R Lima; J Bacalcthuk; T R E Barnes; K Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

8.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

Review 9.  Postpsychotic depression in schizophrenia patients.

Authors:  Christian G Kohler; Elise A Lallart
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

Review 10.  Neuroleptic dysphoria: towards a new synthesis.

Authors:  L Voruganti; A G Awad
Journal:  Psychopharmacology (Berl)       Date:  2003-11-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.